 |
|
Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
Cheol-Hyung Lee, Yun Bin Lee, Minseok Albert Kim, Heejoon Jang, Hyunwoo Oh, Sun Woong Kim, Eun Ju Cho, Kyung-Hun Lee, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Tae-You Kim, Yoon Jun Kim
Clin Mol Hepatol. 2020;26(3):328-339. Published online 2020 May 28 DOI: https://doi.org/10.3350/cmh.2019.0049n
|
|
Citations to this article as recorded by
 Impact of post‐progression survival in second‐line treatment with molecular target agents for unresectable hepatocellular carcinoma
Kazuto Tajiri, Nozomu Muraishi, Aiko Murayama, Yuka Hayashi, Ichiro Yasuda
Hepatology Research.2024; 54(4): 403. CrossRef Approved immune checkpoint inhibitors in hepatocellular carcinoma: a large-scale meta-analysis and systematic review
Ruyi Zhang, Fang Wang, Zhiyu You, Dongyang Deng, Jiangyan He, Wentao Yan, Jian Quan, Jing Wang, Shujuan Yan
Journal of Cancer Research and Clinical Oncology.2024;[Epub] CrossRef Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma
Hong Jun Lee, Jae Seung Lee, Hyesung So, Ja Kyung Yoon, Jin-Young Choi, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim
Yonsei Medical Journal.2024; 65(7): 371. CrossRef Nivolumab as Second-Line Therapy Improves Survival in Patients with Unresectable Hepatocellular Carcinoma
Faisal M. Sanai, Hassan O. Odah, Kanan Alshammari, Adnan Alzanbagi, Murooj Alsubhi, Hani Tamim, Ashwaq Alolayan, Ahmed Alshehri, Saleh A. Alqahtani
Cancers.2024; 16(12): 2196. CrossRef Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis
Yuwei Liu, Jiahui Pan, Fangbo Gao, Wentao Xu, Hongyu Li, Xingshun Qi
Advances in Therapy.2023; 40(2): 521. CrossRef Evaluating liver function and the impact of immune checkpoint inhibitors in the prognosis of hepatocellular carcinoma patients: A systemic review and meta-analysis
Bao-Wen Tian, Lun-Jie Yan, Zi-Niu Ding, Hui Liu, Cheng-Long Han, Guang-Xiao Meng, Jun-Shuai Xue, Zhao-Ru Dong, Yu-Chuan Yan, Jian-Guo Hong, Zhi-Qiang Chen, Dong-Xu Wang, Tao Li
International Immunopharmacology.2023; 114: 109519. CrossRef Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma
Yuna Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Myung Ji Goh, Wonseok Kang, Seung Up Kim
European Journal of Gastroenterology & Hepatology.2023; 35(2): 191. CrossRef Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma
Carmelo Laface, Girolamo Ranieri, Felicia Maria Maselli, Francesca Ambrogio, Caterina Foti, Michele Ammendola, Marigia Laterza, Gerardo Cazzato, Riccardo Memeo, Giovanni Mastrandrea, Marco Lioce, Palma Fedele
Cancers.2023; 15(3): 654. CrossRef 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Journal of Liver Cancer.2023; 23(1): 1. CrossRef Prognostic factors of nivolumab in advanced hepatocellular carcinoma: a systematic review and meta-analysis
Ding XIONG, Kui ZHANG, Mingqing XU
Panminerva Medica.2023;[Epub] CrossRef Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook
Yinjie Fan, Hang Xue, Huachuan Zheng
Journal of Hepatocellular Carcinoma.2022; Volume 9: 233. CrossRef Intrahepatic inflammatory IgA+PD-L1high monocytes in hepatocellular carcinoma development and immunotherapy
Pil Soo Sung, Dong Jun Park, Pu Reun Roh, Kyoung Do Mun, Sung Woo Cho, Gil Won Lee, Eun Sun Jung, Sung Hak Lee, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Jonghwan Choi, Jaegyoon Ahn, Seung Kew Yoon
Journal for ImmunoTherapy of Cancer.2022; 10(5): e003618. CrossRef Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma
Kuo-Wei Huang, Pei-Chang Lee, Yee Chao, Chien-Wei Su, I-Cheng Lee, Keng-Hsin Lan, Chi-Jen Chu, Yi-Ping Hung, San-Chi Chen, Ming-Chih Hou, Yi-Hsiang Huang
Therapeutic Advances in Medical Oncology.2022; 14: 175883592210994. CrossRef 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Clinical and Molecular Hepatology.2022; 28(4): 583. CrossRef 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
Korean Journal of Radiology.2022; 23(12): 1126. CrossRef Blood-based biomarkers for immune-based therapy in advanced HCC: Promising but a long way to go
Pil Soo Sung, Isaac Kise Lee, Pu Reun Roh, Min Woo Kang, Jaegyoon Ahn, Seung Kew Yoon
Frontiers in Oncology.2022;[Epub] CrossRef Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea
Min Jin Lee, Sung Won Chang, Ji Hoon Kim, Young-Sun Lee, Sung Bum Cho, Yeon Seok Seo, Hyung Joon Yim, Sang Youn Hwang, Hyun Woong Lee, Young Chang, Jae Young Jang
Investigational New Drugs.2021; 39(1): 260. CrossRef Targeted treatment of alcoholic liver disease based on inflammatory signalling pathways
Bingjian Wen, Chengcheng Zhang, Jingwen Zhou, Zhengyan Zhang, Qishi Che, Hua Cao, Yan Bai, Jiao Guo, Zhengquan Su
Pharmacology & Therapeutics.2021; 222: 107752. CrossRef Surgery versus external beam radiotherapy for hepatocellular carcinoma involving the inferior vena cava or right atrium: A systematic review and meta‐analysis
Han Ah Lee, Sunmin Park, Yeon Seok Seo, Won Sup Yoon, In‐Soo Shin, Chai Hong Rim
Journal of Hepato-Biliary-Pancreatic Sciences.2021; 28(12): 1031. CrossRef The Efficacy and Safety of Programmed Death-1 and Programmed Death Ligand 1 Inhibitors for the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Shukang He, Weichao Jiang, Kai Fan, Xiaobei Wang
Frontiers in Oncology.2021;[Epub] CrossRef Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma
Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim
Journal of Cancer Research and Clinical Oncology.2021; 147(10): 3123. CrossRef Evolving therapeutic strategies for advanced hepatocellular carcinoma
Ammar Qureshi, Miguel Michel, Jaren Lerner, Constantin A. Dasanu
Expert Opinion on Pharmacotherapy.2021; 22(18): 2495. CrossRef Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1
Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho
International Journal of Molecular Sciences.2021; 22(18): 10027. CrossRef Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
Yuan-Hung Kuo, Yi-Hao Yen, Yen-Yang Chen, Kwong-Ming Kee, Chao-Hung Hung, Sheng-Nan Lu, Tsung-Hui Hu, Chien-Hung Chen, Jing-Houng Wang
Frontiers in Oncology.2021;[Epub] CrossRef Knockdown of Atg7 suppresses Tumorigenesis in a murine model of liver cancer
Kyung Joo Cho, Sun Yeong Shin, Hyuk Moon, Beom Kyung Kim, Simon Weonsang Ro
Translational Oncology.2021; 14(9): 101158. CrossRef Systemic therapy for advanced hepatocellular carcinoma: consideration for selecting second-line treatment
Bo Hyun Kim, Joong-Won Park
Journal of Liver Cancer.2021; 21(2): 124. CrossRef Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review
Kyoko Oura, Asahiro Morishita, Joji Tani, Tsutomu Masaki
International Journal of Molecular Sciences.2021; 22(11): 5801. CrossRef Potential predictors for survival in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: A meta-analysis
Huilin Xu, Dedong Cao, Yongfa Zheng, Dingjie Zhou, Xin Chen, Jinju Lei, Wei Ge, Ximing Xu
International Immunopharmacology.2021; 100: 108135. CrossRef Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study
Jaejun Lee, Ji-Won Han, Pil-Soo Sung, Soon-Kyu Lee, Hyun Yang, Hee-Chul Nam, Sun-Hong Yoo, Hae-Lim Lee, Hee-Yeon Kim, Sung-Won Lee, Jung-Hyun Kwon, Jeong-Won Jang, Chang-Wook Kim, Soon-Woo Nam, Jung-Suk Oh, Ho-Jong Chun, Si-Hyun Bae, Jong-Young Choi, Seun
Journal of Clinical Medicine.2021; 10(18): 4045. CrossRef Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma
Sojung Han, Do Young Kim
Clinical and Molecular Hepatology.2020; 26(3): 305. CrossRef Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
Mohamed A. Abd El Aziz, Antonio Facciorusso, Tarek Nayfeh, Samer Saadi, Mohamed Elnaggar, Christian Cotsoglou, Rodolfo Sacco
Vaccines.2020; 8(4): 616. CrossRef Nivolumab/regorafenib
Reactions Weekly.2020; 1830(1): 253. CrossRef
|